Clear All
767 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Encorafenib Braftovi 50mg, 75mg Chemotherapy BRAF Inhibitor V600E Yes 2018 In Use
NA Estrogens, Esterified Covaryx, Covaryx H.S., Menest, Ogen, Ortho-Est 0.3 mg Hormonal Therapy Estrogen Yes 1977 In Use
J9264 Paclitaxel Abraxane, protein bound 1 mg Chemotherapy Antimitotic Agent Taxane No 1992 Jan 1, 2006 In Use
NA Tucatinib Tukysa 50mg,150mg Chemotherapy Tyrosine Kinase Inhibitor HER2 Yes 2020 In Use
NA Vandetanib Caprelsa 300 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, EGFR Yes 2011 In Use
Vorasidenib Voranigo 10mg,40mg Chemotherapy IDH Inhibitor IDH1, IDH2 Yes 2024 In Use
J9293 Mitoxantrone Mitoxantrone pr 5 mg Chemotherapy Antitumor Antibiotic Anthracenedione No 1987 Jan 1, 1990 In Use
Q5146 Trastuzumab-strf (hercessi) Hercessi 10mg Immunotherapy Monoclonal Antibody HER2 No 2025 Jan 1, 2025 In Use
Vimseltinib Romvimza 14mg, 20mg, 30mg Chemotherapy Tyrosine Kinase Inhibitor CSF1R Yes 2025 In Use
Q2049 Doxorubicin Doxil 10 mg Chemotherapy Antitumor Antibiotic Anthracycline No 1995 Jul 1, 2012 In Use
NA Estrogens, Esterified Covaryx, Covaryx H.S., Menest, Ogen, Ortho-Est 1.25 mg Hormonal Therapy Estrogen Yes 1977 In Use
J9380 Teclistamab cqyv Tecvayli 0.5mg Immunotherapy Monoclonal Antibody BCMA, CD3 No 2022 Jul 11, 2023 In Use
J9350 Mosunetuzumab-axgb Lunsumio 1mg Immunotherapy Monoclonal Antibody CD20, CD3 No 2022 Jul 11, 2023 In Use
Q2053 Brexucabtagene autoleucel Tecartus 2000000 Immunotherapy CAR-T CD-19 No 2020 Apr 1, 2021 In Use
NA Pexidartinib Turalio Multiple Chemotherapy Tyrosine Kinase Inhibitor CSF1R, KIT, FLT3 Yes 2019 In Use
NA Gardasil-9 Human papillomavirus vaccine Ancillary Therapy Protective Agent HPV Vaccine No 2016 In Use
S9338 Immunotherapy - non specific Home infusion therapy, immunotherapy NA Immunotherapy No Jan 1, 2002 In Use
J9151 Daunorubicin DaunoXome 10 mg Chemotherapy Antitumor Antibiotic Anthracycline No 1996 Jan 1, 1999 In Use
NA Diethylstilbestrol DES, Stilbestrol unspecified Hormonal Therapy Estrogen Yes 1905 2000 In Use
Q0166 Granisetron Hydrochloride Granisol [DSC], Sancuso, Sustol, Kytril 1 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1993 Jan 1, 2009 In Use
J2468 Palonosetron hydrochloride (avyxa) Palonosetron hydrochloride (avyxa) 25 MCG Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 2016 Jun 10, 2024 In Use
J9390 Vinorelbine Navelbine 10 mg Chemotherapy Antimitotic Agent Vinca Alkaloid No 1994 Jan 1, 1996 In Use
NA Ketoconazole Apo-Ketoconazole 200 mg Hormonal Therapy Androgen Receptor Inhibitor Imidazole Derivative Yes 1981 In Use
J1010 Methylprednisolone acetate Methylprednisolone acetate 1mg Hormonal Therapy Adrenal Glucocorticoid Corticosteroid No 1959 Apr 17, 2024 In Use
J9357 Valrubicin Valstar 200 mg Chemotherapy Antitumor Antibiotic Anthracycline No 1998 Jan 1, 2000 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.